Jiangsu Hengrui Pharmaceuticals stock
Price history
−22.48% over the period1 year: from ¥60.63 (November 20, 2025) to ¥47.00 (November 20, 2026), −22.48%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | ¥47.00 |
| October 30, 2026 | ¥48.46 |
| September 30, 2026 | ¥47.20 |
| August 31, 2026 | ¥46.07 |
| July 31, 2026 | ¥54.08 |
| June 30, 2026 | ¥52.04 |
| May 29, 2026 | ¥50.19 |
| April 30, 2026 | ¥53.88 |
| March 31, 2026 | ¥55.22 |
| February 27, 2026 | ¥56.56 |
| January 30, 2026 | ¥58.16 |
| December 31, 2025 | ¥59.57 |
| November 28, 2025 | ¥62.08 |
| November 20, 2025 | ¥60.63 |
At a glance
The company
Develops, manufactures and commercializes pharmaceutical medicines across oncology, cardiovascular, immunological, neuroscience, pain management and other therapeutic areas
Latest results
Quarter to September 30, 2026 · EPS ¥0.37 (estimate ¥0.34)
Next event
TickerLandia's take on Jiangsu Hengrui Pharmaceuticals
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 40 vs a median of 62 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 35 vs 41 (−15%) in a group of 11.
- Strong point: Financial strength (96/100 in its group). Weak point: Market momentum (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−28.60% from the 52-week high
Analysts · 18 analysts
Average target¥71.64+52.42% vs. price
Buy 18 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Jiangsu Hengrui Pharmaceuticals
Compared with similar companies: very high financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh76
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 35.1 67 Forward P/E 30.9 76 EV/EBITDA 27.5 82 Price/book 4.64 71 Price/sales 9.50 86 Profitabilityhigh73
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 27.4% 76 ROE 13.9% 53 Net margin 27.0% 83 ROA 7.8% 60 Gross margin 86.4% 94 Earnings stabilityaverage48
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.0% 33 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage40
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +14.13% 78 Revenue growth (year over year) −14.50% 4 Earnings growth (year over year) −14.60% 39 Financial strengthvery high96
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −4.60 96 Interest coverage 563.5 96 Debt/equitycounts in reverse: lower means more financial strength 0.00 96 Current ratio 7.91 96 Dividendlow35
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 14.9% 18 Consecutive dividend years at least 26 years 68 Dividend yield 0.4% 18 Market momentumweak33
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −22.48% 19 Distance from 200-day average −9.21% 47 Riskaverage40
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 33.9% 50 Volatility (60 days) 29.5% 31
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Jiangsu Hengrui Pharmaceuticals is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Jiangsu Hengrui Pharmaceuticals's P/E today is 39.8, below the median of its last 10 fiscal years (62.1; between 41.3 and 93.8 from 2016 to 2025). Jiangsu Hengrui Pharmaceuticals's P/E (trailing 12 months): 35.1, −15% against the median of a group of 11 similar companies (41.2).
Compared with 11 similar companies
| Metric | Jiangsu Hengrui Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 35.1 | Middle | |
| Forward P/E | 30.9 | Middle | |
| Operating margin | 27.4% | Middle | |
| ROE | 13.9% | Middle | |
| Debt/equity | 0.00 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Jiangsu Hengrui Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥8.95B
Latest quarter · Q3 2026
Net income
¥2.46B
Latest quarter · Q3 2026
Quarterly net margin
27.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥311.95B
- P/E
- 35.1
- EPS
- ¥1.34
- Volume
- 54.69M
- Daily trading
- €384.65M
- Dividend yield
- 0.43%
- Last ex-dividend on May 27, 2026
How Jiangsu Hengrui Pharmaceuticals is changing
All resultsRevenue grew 2.7% a year on average over the last 5 years
Operating margin rose from 14.4% to 25.6%
Profits turn into cash: free cash flow equal to 108% of net income
Returns
Jiangsu Hengrui Pharmaceuticals returns with dividends
¥1,000 invested in Jiangsu Hengrui Pharmaceuticals 5 years ago, on November 22, 2021, would be worth ¥922 today with dividends reinvested: −7.83% in total, −1.62% per year. On price alone it would be ¥903 (−9.65%).
| Period | Jiangsu Hengrui Pharmaceuticals | ¥1,000 becomes |
|---|---|---|
| 1 month | −0.95% | ¥991 |
| 6 months | −7.75% | ¥922 |
| Year to date | −21.10% | ¥789 |
| 1 year | −22.17% | ¥778 |
| 3 years | +0.21% | ¥1,002 |
| 5 years | −7.83% | ¥922 |
| 10 years | +185.57% | ¥2,856 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Jiangsu Hengrui Pharmaceuticals: technical analysis
Jiangsu Hengrui Pharmaceuticals shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 51.0% below its all-time closing high (¥95.84, December 25, 2020).
- Trend
- No clear trend
- RSI (14 sessions)
- 45
- Between 30 and 70
- vs 200-session average
- −9.21%
Support and resistance
Price areas where Jiangsu Hengrui Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥55.98+19.11%2 touches, last on August 10, 2026
- Resistance¥52.40+11.49%5 touches, last on August 7, 2026
- Resistance¥51.05+8.61%2 touches, last on November 6, 2026
- Last price¥47.00
- Support¥45.32−3.57%2 touches, last on October 23, 2026
- Support¥44.54−5.24%2 touches, last on October 14, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 29.5%
- Largest fall in the last year
- −33.87%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Jiangsu Hengrui Pharmaceuticals: seasonality
Average monthly price change over 26 years
Over the last 26 years, the strongest month for Jiangsu Hengrui Pharmaceuticals has been September: +4.51% on average, positive in 20 years out of 26. The weakest has been January: −1.08% on average, positive in 11 years out of 26. November, the current month, has been positive in 15 years out of 26 (+2.01% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.08% | −1.53% | 11 of 26 |
| February | +1.91% | +1.56% | 14 of 26 |
| March | +3.32% | +2.93% | 15 of 26 |
| April | +3.34% | +1.62% | 17 of 26 |
| May | +2.44% | +2.22% | 15 of 26 |
| June | +0.35% | +1.90% | 14 of 26 |
| July | +1.73% | +1.24% | 16 of 26 |
| August | −0.22% | −0.13% | 13 of 26 |
| September | +4.51% | +4.57% | 20 of 26 |
| October | +1.01% | +0.99% | 13 of 26 |
| November | +2.01% | +1.72% | 15 of 26 |
| December | +3.00% | +1.36% | 14 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Jiangsu Hengrui Pharmaceuticals and its competitors
Patients and healthcare providers in China and abroad are the people Jiangsu Hengrui Pharmaceuticals serves with medicines it researches, develops, manufactures and commercializes to address clinical needs that remain unmet. Its medicines cover oncology, metabolic and cardiovascular diseases, immunological and respiratory conditions, neuroscience, pain management, infectious diseases, hematological disorders, ophthalmology and autoimmune illnesses, among other areas.
- Headquarters
- Lianyungang, China
- Employees
- 20,602
- Founded
- 1970
- Chief executive
- Ji Feng
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals600276 | $46.71B | 27.4% | 35.1 | −7.75% |
| Sun Pharmaceutical IndustriesSUNPHARMA | $48.8B | 23.3% | 41.2 | +0.24% |
| Divi's LaboratoriesDIVISLAB | $32.03B | 34.0% | 88.2 | +62.20% |
| Takeda Pharmaceutical4502 | $70.21B | 16.6% | 312.4 | +32.69% |
| Hansoh Pharmaceutical Group3692 | $23.77B | 37.3% | 25.0 | −8.51% |
| Torrent PharmaceuticalsTORNTPHARM | $19.25B | 22.2% | 79.2 | +5.88% |
Same industry or related industries, similar size. Compare Jiangsu Hengrui Pharmaceuticals with its competitors · Full profile
More on Jiangsu Hengrui Pharmaceuticals
- Jiangsu Hengrui Pharmaceuticals revenue and financials
- Jiangsu Hengrui Pharmaceuticals dividend and valuation
- Jiangsu Hengrui Pharmaceuticals stock return
- Jiangsu Hengrui Pharmaceuticals employees, headquarters and business
